中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

恩替卡韦临床应用专家共识:2015年更新

恩替卡韦临床应用专家委员会

恩替卡韦临床应用专家委员会. 恩替卡韦临床应用专家共识:2015年更新[J]. 临床肝胆病杂志, 2016, 32(1): 32-39. DOI: 10.3969/j.issn.1001-5256.2016.01.004
引用本文: 恩替卡韦临床应用专家委员会. 恩替卡韦临床应用专家共识:2015年更新[J]. 临床肝胆病杂志, 2016, 32(1): 32-39. DOI: 10.3969/j.issn.1001-5256.2016.01.004
Expert Committee for Clinical Application of Entecavir. Expert consensus on clinical application of entecavir: an update in 2015[J]. J Clin Hepatol, 2016, 32(1): 32-39. DOI: 10.3969/j.issn.1001-5256.2016.01.004
Citation: Expert Committee for Clinical Application of Entecavir. Expert consensus on clinical application of entecavir: an update in 2015[J]. J Clin Hepatol, 2016, 32(1): 32-39. DOI: 10.3969/j.issn.1001-5256.2016.01.004

恩替卡韦临床应用专家共识:2015年更新

DOI: 10.3969/j.issn.1001-5256.2016.01.004
详细信息
  • 中图分类号: R512.62

Expert consensus on clinical application of entecavir: an update in 2015

  • 摘要:

    <正>恩替卡韦(entecavir,ETV)是当前慢性乙型肝炎(CHB)患者抗病毒治疗的一线药物之一。2005年美国食品药品监督管理局与中国国家食品药品监督管理局相继批准ETV用于CHB治疗。为了规范与优化ETV的临床应用,《中华实验和临床感染病杂志(电子版)》编辑部、《中国肝脏病杂志(电子版)》编辑部曾于2009年邀请国内部分感染病学与肝病学领域专家召开了ETV临床应用专家研讨会,讨论形成了《2009年恩替卡韦临床应用专家共识》;并于2014年对该共识进行更新。近1年来,ETV治疗CHB患者的大样本长期随访数据不断公布,ETV治疗

     

  • [1]SHIFFMAN RN,SHEKELLE P,OVERHAGE JM,et al.Standardized reporting of clinical practice guidelines:a proposal from the conference on guideline standardization[J].Ann Intern Med,2003,139(6):493-498.
    [2]GUYATT GH,OXMAN AD,VIST GE,et al.GRADE:an emerging consensus on rating quality of evidence and strength of recommendations[J].BMJ,2008,336(7650):924-926.
    [3]INNAIMO SF,SEIFER M,BISACCHI GS,et al.Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus[J].Antimicrob Agents Chemother,1997,41(7):1444-1448.
    [4]CHANG TT,GISH RG,de MAN R,et al.A comparison of entecavir and lamivudine for HBeA g-positive chronic hepatitis B[J].N Engl J Med,2006,354(10):1001-1010.
    [5]GISH RG,LOK AS,CHANG TT,et al.Entecavir therapy for up to96 weeks in patients with HBeA g-positive chronic hepatitis B[J].Gastroenterology,2007,133(5):1437-1444.
    [6]LEUNG N.Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues[J].Hepatol Int,2008,2(2):163-178.
    [7]CHANG TT,LAI CL,KEW YOON S,et al.Entecavir treatment up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B[J].Hepatology,2010,51(2):422-430.
    [8]LAI CL,SHOUVAL D,LOK AS,et al.Entecavir versus lamivudine for patients with HBeA g-negative chronic hepatitis B[J].N Engl J Med,2006,354(10):1011-1020.
    [9]SHOUVAL D,AKARCA US,HATZIS G,et al.Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeA g(-)chronic hepatitis B patients(study ETV-027)[J].J Hepatol,2006,44(Suppl 2):s21-s22.
    [10]SHOUVAL D,LAI CL,CHANG TT,et al.Three years of entecavir(ETV)re-treatment of HBeA g(-)patients who previously discontinued ETV treatment:results from study ETV-901[J].Hepatology,2008,4(Suppl 1):722a.
    [11]YAO G.Entecavir is a potent anti-HBV drug superior to lamivudine:experience from clinical trials in China[J].J Antimicrob Chemother,2007,60(2):201-205.
    [12]YAO G,CHEN C,LU W,et al.Virologic,serologic,and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-nave chinese patients with chronic hepatitis B:a randomized,multicenter study[J].Hepatol Int,2008,2(4):486-493.
    [13]YAO GB,XU DZ,REN H,et al.Three years of continuous treatment with entecavir results in high proprotions of chinese nucleoside-naive patients with undetectable HBV DNA:results from studies ETV-023 and-050[J].J Hepatol,2009,48(Suppl 2):s266-s267.
    [14]XU JH,YU YY,SI CW,et al.A randomized,double-blind,double-dummy,controlled,multicenter study of entecavir maleate versus entecavir for treatment of HBeA g-negative chronic hepatitis B:results at week 48[J].Chin J Hepatol,2012,20(7):512-516.(in Chinese)徐京杭,于岩岩,斯崇文,等.马来酸恩替卡韦片治疗HBeA g阴性慢性乙型肝炎的随机、双盲、双模拟对照、多中心临床研究48周结果[J].中华肝脏病杂志,2012,20(7):512-516.
    [15]YU YY,XU JH,TANG H,et al.Entecavir maleate versus entecavir in Chinese patients with HBeA g positive chronic hepatitis B:results at 48 and 96 weeks of a randomized double-blinded multicenter clinical trial[J].Hepatology,2012,48(Suppl 1):s417.
    [16]CHO JY,LEE JH,SOHN W,et al.Long-term entecavir therapy in treatment-nave Asian chronic hepatitis B patients[J].Hepatol Intel,8(Suppl):s127-s128.
    [17]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
    [18]MOCHIDA S,TAKAGUCHI K,YOKOSUKA O,et al.Long term efficacy,safety and resistance analyses of entecavir(ETV)treatment in Japanese nucleoside-nave patients with chronic hepatitis B(CHB)[J].J Hepatol,2008,48(Suppl 2):s262.
    [19] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.
    [20]LIAW YF,KAO JH,PIRATVISUTH T,et al.Asian-Pacific consensus statement on the management of hronic hepatitis B:a 2012update[J].Hepatol Int,2012,6(3):531-561.
    [21]SETO WK,HUI AJ,WONG VW,et al.Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B:a multicentre prospective study[J].Gut,2014,64(4):667-672.
    [22]SHERMAN M,YURDAYDIN C,SIMSEK H,et al.Entecavir therapy for lamivudine-refractory chronic hepatitis B:improved virologic,biochemical and serology outcomes through 96 weeks[J].Hepatology,2008,48(1):99-108.
    [23]LO AO,WONG VW,WONG GL,et al.Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine[J].Antivir Ther,2013,18(5):671-679.
    [24]ZENG T,XU H,LIU JY,et al.Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B:a meta-analysis[J].J Clin Pharmacol,2014,54(9):959-967.
    [25]LEUNG N,LAI CL,ELION R,et al.Entecavir(ETV)therapy in chronic hepatitis B patients previously treated with adefovir(ADV)with incomplete response on-treatment or relapse off-treatment[J].J Hepatol,2009,50(9):s334.
    [26]NGUYEN MH,TRINH HN,DO ST,et al.Complete viral suppression(CVS)rates at year 2 in adefovir-experienced chronic hepatitis B(CHB)patients who were switched to entecavir monotherapy:a multicenter study[J].Hepatology,2011,54(Suppl 1):s73.
    [27]ZOUTENDIJK R,REIJNDERS JGP,BROWN A,et al.Entecavir treatment is effective in patients with previous adefovir treatment:results from an international multicenter cohort study[J].J Hepatol,2011,54(Suppl 1):s306.
    [28]XU XH,LI GL,QIN Y,et al.Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice[J].Virol J,2013,10:162-167.
    [29]PARK JY,KIM CW,BAE SH,et al.Entecavir plus tenofovir combination therapy in patients with multi-drug resistanct chronic hepatitis B:the 48-week results of a multiventer,prospective study[J].Hepatology,2014,60(Suppl 1):s1096.
    [30]SU TH,HU TH,LIN CC,et al.Reduction of hepatocellular carcinoma in hepatitis B-related cirrhosis patients with long-term entecavir therapy-an interim report of C-team study[J].Hepatology,2013,58(Suppl):301a.
    [31]HOSAKA T,SUZUKI F,KOBAYASHI M,et al.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection[J].Hepatology,2013,58(1):98-107.
    [32]WONG GL,CHAN HL,MAK CW,et al.Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis[J].Hepatology,2013,58(5):1537-1547.
    [33]CHANG TT,LIAW YF,WU SS,et al.Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in chronic hepatitis B patients[J].Hepatology,2010,52(3):886-893.
    [34]KUO YH,LU SN,CHEN CH,et al.The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy[J].PLoS One,2014,9(3):e93160.
    [35]Liver Cancer Study Group,Chinese Society of Hepatology,Chinese Medical Association.Recommendation on antiviral therapy to hepatitis B/C virus related hepatocellular carcinoma[J].J Clin Hepatol,2013,29(1):5-9.(in Chinese)中华医学会肝病学分会肝癌学组.HBV/HCV相关性肝细胞癌抗病毒治疗专家建议[J].临床肝胆病杂志,2013,29(1):5-9.
    [36]WU CY,CHEN YJ,HO HJ,et al.Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection[J].JAMA,2012,308(18):1906-1914.
    [37]LAO XM,LUO G,YE LT,et al.Effects of antiviral therapy on hepatitis b virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma[J].Liver Int,2013,33(4):595-604.
    [38] Liver Failure and Artificial Liver Group,Chinese Severe Liver Diseases and Artificial Liver Group.Diagnostic and treatment guidelines for liver failure(2012 version)[J].Chin J Hepatol,2013,21(3):177-183.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版)[J].中华肝脏病杂志,2013,21(3):177-183.
    [39]ZHAO H,WANG GS,XIE W,et al.Efficacy of entecavir on liver failure patients with chronic hepatitis B[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition,2011,5(2):188-194.(in Chinese)赵红,王桂爽,谢雯,等.恩替卡韦治疗乙型肝炎慢性肝衰竭的疗效观察[J/CD].中华实验和临床感染病杂志:电子版,2011,5(2):188-194.
    [40]ZHANG Y,HU XY,ZHONG S,et al.Entecavir vs lamivudine therapy for naive patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure[J].World J Gastroenterol,2014,20(16):4745-4752.
    [41]CHEN FW,COYLE L,JONES BE,et al.Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease[J].Liver Int,2013,33(8):1203-1210.
    [42]HUANG YH,HSIAO LT,HONG YC,et al.Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B[J].J Clin Oncol,2013,31(22):2765-2772.
    [43]PERILLO R,BUTI M,DURAND F,et al.Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B[J].Liver Transpl,2013,19(8):887-895.
    [44]YI NJ,CHOI JY,SUH KS,et al.Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin[J].J Gastroenterol,2013,48(12):1401-1410.
    [45] AIDS Group,Society of Infectious Diseases,Chinese Medical Association.Guideline of diagnosis and treatment for AIDS[J].Chin J Clin Infect Dis,2011,4(6):321-330.(in Chinese)中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南(2011版)[J].中华临床感染病杂志,2011,4(6):321-330.
    [46]McM AHON MA,JILEK BL,BRENNAN TP,et al.The HBV drug entecavir-effects on HIV-1 replication and resistance[J].N Engl J Med,2007,356(25):2614-2621.
    [47]PAWLOWSKA M,HALOTA W,SMUKALSKA E,et al.HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B[J].Eur J Clin Microbiol Infect Dis,2012,31(4):571-574.
    [48]The Antiretroviral Pregnancy Registry.Interim Report:1 January 1989through 31 January 2013[R/OL].[2013-09-30].http://www.apregistry.com/forms/interim_report.pdf.
    [49]CAI HD,MA XY,LI RQ,et al.Retrospective survey assessing pregnancy outcomes of partners of Chinese male patients with chronic hepatitis B who received long-term entecavir treatment[J].Liver Int,2014,36(Suppl):s654.
    [50]PENG J,HOU JL.Current situation and management of pregnancy and anti-HBV treatment[J].Chin J Hepatol,2011,19(3):236-238.(in Chinese)彭劼,侯金林.妊娠与抗乙型肝炎病毒治疗的现状与管理[J].中华肝脏病杂志,2011,19(3):236-238.
    [51] ZHUNG H,WENG XH.Development and management of drug resistance to nucleoside/nucleotide analogues in patients with chronic hepatitis B[J].Chin J Hepatol,2013,21(1):15-22.(in Chinese)庄辉,翁心华.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理[J].中华肝脏病杂志,2013,21(1):15-22.
    [52]KIM YJ,SINN DH,GWAK GY,et al.Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures[J].World J Gastroenterol,2012,18(47):6996-7002.
    [53]SARRECCHIA C,SVICHER V,VOLPI A,et al.Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance[J].Infection,2011,39(4):367-370.
    [54]PETERSEN J,RATZIU V,BUTI M,et al.Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients:an international multicenter cohort study[J].J Hepatol,2012,56(3):520-526.
    [55]KIM SS,CHEONG JY,LEE D,et al.Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B[J].J Med Virol,2012,84(1):18-25.
    [56]LANGE CM,BOJUNGA J,HOFMANN WP,et al.Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function[J].Hepatology,2009,50(6):2001-2006.
    [57]YUAN K,GUOCHUN W,HUANG Z,et al.Entecavir-associated myopathy:a case report and literature review[J].Muscle Nerve,2014,49(4):610-614.
  • 加载中
计量
  • 文章访问数:  23
  • HTML全文浏览量:  6
  • PDF下载量:  834
  • 被引次数: 0
出版历程
  • 刊出日期:  2016-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回